Back to top
more

Sera Prognostics (SERA)

(Delayed Data from NSDQ)

$2.59 USD

2.59
95,513

-0.11 (-4.07%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $2.60 +0.01 (0.39%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

After Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)

by Zacks Equity Research

Sera Prognostics (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Down -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a Turnaround

by Zacks Equity Research

Sera Prognostics (SERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sera Prognostics (SERA) delivered earnings and revenue surprises of 16.67% and 62%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sera Prognostics (SERA) delivered earnings and revenue surprises of -8.70% and 20%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HealthEquity (HQY) Q4 Earnings Miss Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of -2.82% and 2.20%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Enhabit (EHAB) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Enhabit (EHAB) delivered earnings and revenue surprises of -20% and 0.37%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sotera Health Company (SHC) Meets Q4 Earnings Estimates

by Zacks Equity Research

Sotera Health (SHC) delivered earnings and revenue surprises of 0% and 0.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sera Prognostics (SERA) delivered earnings and revenue surprises of -9.09% and 67.78%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sera Prognostics (SERA) delivered earnings and revenue surprises of -8.70% and 70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pediatrix Medical Group (MD) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 9.68% and 0.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cencora (COR) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Cencora (COR) delivered earnings and revenue surprises of 5.03% and 0.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Avantor, Inc. (AVTR) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Avantor (AVTR) delivered earnings and revenue surprises of 8.70% and 0.01%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Encompass Health (EHC), Piedmont Expand Ties to Serve Georgia

by Zacks Equity Research

Encompass Health (EHC) expands its partnership with Piedmont to better serve Georgians with the Walton Rehabilitation Hospital.

Zacks Equity Research

Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7%

by Zacks Equity Research

AI can help Teladoc (TDOC) to streamline healthcare delivery, making it more efficient and scalable.

Zacks Equity Research

Elevance Health (ELV) Rallies 11.8% YTD: More Room to Run?

by Zacks Equity Research

Elevance Health's (ELV) performance benefits from new contract wins, a strong Carelon segment and recovering Medicaid business.

Zacks Equity Research

Brookdale (BKD) Sees 31 Months of Y/Y Occupancy Growth Streak

by Zacks Equity Research

Brookdale's (BKD) weighted average occupancy for the second quarter-to-date rises 160 bps year over year to 78%.

Zacks Equity Research

Select Medical (SEM) Rises 42.4% YTD: More Growth Ahead?

by Zacks Equity Research

Select Medical (SEM) will continue to gain from rising admissions within the Critical Illness Recovery Hospital and Rehabilitation Hospital segments.

Zacks Equity Research

Will UnitedHealth (UNH) Dividend Hike Fail to Excite Investors?

by Zacks Equity Research

UnitedHealth's (UNH) strong financial position supports its shareholder value boosting efforts.

Zacks Equity Research

Cigna's (CI) Express Scripts Collaborates With CPESN USA

by Zacks Equity Research

Cigna's (CI) Express Scripts collaborates with CPESN USA in a bid to enhance care delivery for hypertension and diabetes patients.

Zacks Equity Research

Encompass Health (EHC) JV Opens Atlanta Rehabilitation Hospital

by Zacks Equity Research

The new facility in Georgia marks the 162nd inpatient rehabilitation hospital of Encompass Health (EHC) in the country.

Zacks Equity Research

Encompass Health (EHC) Opens Rehabilitation Hospital in Ballwin

by Zacks Equity Research

The 40-bed inpatient rehabilitation hospital is a JV between Encompass Health (EHC) and BJC HealthCare.

Zacks Equity Research

Elevance (ELV) Rises 14.9% YTD: What Lies Ahead for Investors?

by Zacks Equity Research

Elevance (ELV) continues to focus on increasing shareholder value with consistent dividend payouts and stock repurchases.

Zacks Equity Research

Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Sera Prognostics (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sera Prognostics (SERA) delivered earnings and revenue surprises of 0% and 56.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Sera Prognostics, Inc. (SERA) have what it takes to be a top stock pick for momentum investors? Let's find out.